PE20170774A1 - Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos - Google Patents
Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismosInfo
- Publication number
- PE20170774A1 PE20170774A1 PE2017000231A PE2017000231A PE20170774A1 PE 20170774 A1 PE20170774 A1 PE 20170774A1 PE 2017000231 A PE2017000231 A PE 2017000231A PE 2017000231 A PE2017000231 A PE 2017000231A PE 20170774 A1 PE20170774 A1 PE 20170774A1
- Authority
- PE
- Peru
- Prior art keywords
- kinase inhibitors
- fgfr kinase
- compounds
- preparation
- indazol
- Prior art date
Links
- 108091008794 FGF receptors Proteins 0.000 title abstract 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- -1 6- (2,6-dichloro-3,5-dimethoxyphenyl) -1H-indazol-3-yl Chemical group 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- STGTYMWAEYUNQI-UHFFFAOYSA-N C1COCCN1C1=CC=C(C=C1)C(=O)NC1=NNC2=C1C=CC(=C2)C1=C(Cl)C(OC)=CC(OC)=C1Cl Chemical compound C1COCCN1C1=CC=C(C=C1)C(=O)NC1=NNC2=C1C=CC(=C2)C1=C(Cl)C(OC)=CC(OC)=C1Cl STGTYMWAEYUNQI-UHFFFAOYSA-N 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 150000002473 indoazoles Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a compuestos de formula I, donde: L es H o tetrahidropiranilo; X es Cl, F, H o CN; W, Y y Z son N o CH; el anillo A esta ausente o es un grupo arileno de 5 a 8 miembros sustituidos o no sustituidos, entre otros; R es H o cualquiera de los grupos i, ii, entre otros; M es alquileno C1-C6 sustituido o no sustituido, entre otros. Son compuestos preferidos: N-(6-(2,6-dicloro-3,5-dimetoxifenil)-1H-indazol-3-il)-4-(4-metilpiperazin-1-il)benzamida; N-(6-(2,6-dicloro-3,5-dimetoxifenil)-1H-indazol-3-il)-4-morfolino-benzamida; 4-((4-acetil-1-il)metil)-N-(6-(2,6-dicloro-3,5-dimetoxifenil)-1H-indazol-3-il)benzamida; entre otros. Tambien se refiere a un metodo de produccion. Dichos compuestos son derivados de indazol inhibidores de la cinasa FGFR, siendo utiles en el tratamiento de cancer endometrial, cancer de mama, entre otros
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410409467 | 2014-08-19 | ||
| CN201510073179 | 2015-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170774A1 true PE20170774A1 (es) | 2017-07-04 |
Family
ID=55350206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000231A PE20170774A1 (es) | 2014-08-19 | 2015-08-19 | Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10562900B2 (es) |
| EP (1) | EP3184521B1 (es) |
| JP (1) | JP6445684B2 (es) |
| KR (2) | KR102166002B1 (es) |
| CN (1) | CN105524048B (es) |
| AU (1) | AU2015306561B2 (es) |
| BR (1) | BR112017003312B1 (es) |
| CA (1) | CA2958503C (es) |
| ES (1) | ES2904544T3 (es) |
| MX (1) | MX2017002206A (es) |
| MY (1) | MY188447A (es) |
| PE (1) | PE20170774A1 (es) |
| RU (1) | RU2719428C2 (es) |
| WO (1) | WO2016026445A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000673T1 (it) | 2012-06-13 | 2021-01-05 | Incyte Holdings Corp | Composti triciclici sostituiti come inibitori di fgfr |
| SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| PE20170774A1 (es) * | 2014-08-19 | 2017-07-04 | Shanghai Haihe Pharmaceutical Co Ltd | Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN106279119B (zh) * | 2015-05-27 | 2020-06-16 | 上海海和药物研究开发有限公司 | 一种新型激酶抑制剂的制备及其应用 |
| CN105601617B (zh) * | 2016-03-24 | 2019-02-22 | 山东省科学院生物研究所 | 一种邻二氮杂环化合物及其制备方法与应用 |
| CN107698593A (zh) * | 2016-08-09 | 2018-02-16 | 南京天印健华医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| CN108570052A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN110317173B (zh) * | 2018-03-30 | 2022-10-11 | 上海奕拓医药科技有限责任公司 | 用作fgfr不可逆抑制剂的酰胺基吡唑类化合物 |
| FI3788047T3 (fi) | 2018-05-04 | 2024-11-02 | Incyte Corp | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi |
| MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
| CN108570049A (zh) * | 2018-07-24 | 2018-09-25 | 上海毕得医药科技有限公司 | 一种6-氯-1氢-吡唑并[3,4-b]吡啶的合成方法 |
| WO2020038458A1 (zh) * | 2018-08-23 | 2020-02-27 | 如东凌达生物医药科技有限公司 | 一类稠环三氮唑类化合物、制备方法和用途 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JOP20220083A1 (ar) * | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP7260718B2 (ja) * | 2019-11-29 | 2023-04-18 | メッドシャイン ディスカバリー インコーポレイテッド | ジアザインドール誘導体及びそのＣｈｋ１阻害剤としての使用 |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN112521336B (zh) * | 2020-02-21 | 2023-03-28 | 温州医科大学 | 一种吲唑类、吡咯并吡啶类化合物及其应用 |
| WO2022015977A1 (en) * | 2020-07-15 | 2022-01-20 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US20230271941A1 (en) * | 2020-07-15 | 2023-08-31 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| CN113735774B (zh) * | 2021-08-31 | 2023-06-09 | 四川大学华西医院 | 一种多激酶抑制剂yth-17的制备方法 |
| CN115869315A (zh) * | 2022-12-01 | 2023-03-31 | 思路迪生物医药(上海)有限公司 | 一种fgfr抑制剂的固体分散体、制剂、其制备方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003245700A1 (en) * | 2002-02-12 | 2003-09-04 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| FR2836915B1 (fr) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| AU2013323508B2 (en) * | 2012-09-28 | 2017-11-02 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
| KR20150095888A (ko) * | 2012-12-19 | 2015-08-21 | 노파르티스 아게 | 오토탁신 억제제 |
| US9266892B2 (en) * | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PE20170774A1 (es) * | 2014-08-19 | 2017-07-04 | Shanghai Haihe Pharmaceutical Co Ltd | Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos |
-
2015
- 2015-08-19 PE PE2017000231A patent/PE20170774A1/es unknown
- 2015-08-19 US US15/504,854 patent/US10562900B2/en active Active
- 2015-08-19 KR KR1020197026420A patent/KR102166002B1/ko active IP Right Grant
- 2015-08-19 JP JP2017509744A patent/JP6445684B2/ja active Active
- 2015-08-19 AU AU2015306561A patent/AU2015306561B2/en active Active
- 2015-08-19 MY MYPI2017000250A patent/MY188447A/en unknown
- 2015-08-19 CA CA2958503A patent/CA2958503C/en active Active
- 2015-08-19 ES ES15833329T patent/ES2904544T3/es active Active
- 2015-08-19 MX MX2017002206A patent/MX2017002206A/es unknown
- 2015-08-19 BR BR112017003312-7A patent/BR112017003312B1/pt active IP Right Grant
- 2015-08-19 WO PCT/CN2015/087556 patent/WO2016026445A1/zh active Application Filing
- 2015-08-19 RU RU2017105781A patent/RU2719428C2/ru active
- 2015-08-19 KR KR1020177007663A patent/KR102022866B1/ko active Application Filing
- 2015-08-19 EP EP15833329.4A patent/EP3184521B1/en active Active
- 2015-08-19 CN CN201510512095.XA patent/CN105524048B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190105679A (ko) | 2019-09-17 |
| AU2015306561A1 (en) | 2017-04-06 |
| EP3184521A4 (en) | 2018-01-03 |
| RU2017105781A3 (es) | 2019-01-21 |
| BR112017003312A2 (pt) | 2018-02-27 |
| KR102166002B1 (ko) | 2020-10-15 |
| EP3184521A1 (en) | 2017-06-28 |
| WO2016026445A1 (zh) | 2016-02-25 |
| US10562900B2 (en) | 2020-02-18 |
| CN105524048B (zh) | 2019-11-12 |
| MY188447A (en) | 2021-12-09 |
| RU2017105781A (ru) | 2018-09-20 |
| KR20170069199A (ko) | 2017-06-20 |
| ES2904544T3 (es) | 2022-04-05 |
| CA2958503C (en) | 2021-01-19 |
| RU2719428C2 (ru) | 2020-04-17 |
| JP6445684B2 (ja) | 2018-12-26 |
| MX2017002206A (es) | 2018-01-23 |
| US20170275291A1 (en) | 2017-09-28 |
| BR112017003312B1 (pt) | 2023-05-02 |
| KR102022866B1 (ko) | 2019-09-19 |
| CN105524048A (zh) | 2016-04-27 |
| CA2958503A1 (en) | 2016-02-25 |
| AU2015306561B2 (en) | 2018-03-15 |
| EP3184521B1 (en) | 2021-10-06 |
| JP2017532293A (ja) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170774A1 (es) | Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos | |
| PE20190395A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| PE20170677A1 (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret) | |
| EA202092442A3 (ru) | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| PE20161427A1 (es) | Inhibidores heteroarilo de syk | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| ECSP16067303A (es) | Heteroarilos y usos de estos | |
| TR201819138T4 (tr) | FGFR Kinaz Modülatörleri Olarak Faydalı Kinoksalin Türevleri | |
| ECSP18024565A (es) | Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| PE20151981A1 (es) | Pontenciador de inhibidores del homologo de zeste | |
| EA201790085A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| MD3386991T2 (ro) | Compuși policiclici ca inhibitori de tirozin kinază Bruton | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| UY32180A (es) | Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1) | |
| EA201171062A1 (ru) | Алкиламидные соединения и их применение | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| EA201891379A1 (ru) | Ингибиторы тирозинкиназы брутона и способы их применения |